Mesoblast (ASX:MSB) Total Long-Term Assets: A$872.64 Mil (As of Dec. 2025)


ASX:MSB Mesoblast Ltd ASX:MSB
40 GF Score
Price A$2.02
! 4 Warning Signs
View Full Analysis

What is Mesoblast Total Long-Term Assets?

Mesoblast ASX:MSB -0.98% 40 Total Long-Term Assets is A$872.64 Mil as of Dec. 2025. GuruFocus rates ASX:MSB with a GF Score™ of 40/100. The stock has 4 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Mesoblast's Total Long-Term Assets for the quarter that ended in Dec. 2025 was A$872.64 Mil.

Mesoblast Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Mesoblast's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Total Long-Term Assets Chart

Mesoblast Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 780.21 842.85 875.76 877.53 891.39

Mesoblast Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 891.39 0.00 872.64 0.00
ASX:MSB
40GF Score
Mesoblast Ltd ASX:MSB
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of A$872.64 Mil mean?
Mesoblast (ASX:MSB) has a Total Long-Term Assets of A$872.64 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Mesoblast and its competitors.
Is Mesoblast's Total Long-Term Assets too high?
Mesoblast's current Total Long-Term Assets is A$872.64 Mil. Overall, Mesoblast has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Total Long-Term Assets compare to VRTX and REGN?
Mesoblast's Total Long-Term Assets of A$872.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Mesoblast and its competitors. Mesoblast's current Total Long-Term Assets is A$872.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current Total Long-Term Assets of A$872.64 Mil. The current Total Long-Term Assets is A$872.64 Mil. Mesoblast's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current Total Long-Term Assets is A$872.64 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
40GF Score

Get the complete analysis for ASX:MSB

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.02
Price